FDA Inspection 1049436 — Ajanta Pharma USA Inc

Ajanta Pharma USA Inc — FEI 3010721419

The FDA completed an inspection of Ajanta Pharma USA Inc on Apr 4, 2018 in Bridgewater, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI)
End Date
Apr 4, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Bridgewater, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.